388 results
8-K
SEEL
Seelos Therapeutics Inc
3 May 24
Entry into a Material Definitive Agreement
5:06pm
be no assurance the Panel will grant any request for continued listing or that the Company will be able to regain compliance with the applicable listing … , among other options, effectuating a reverse stock split. There can be no assurance that the Company will be able to regain compliance with Nasdaq’s
424B3
SEEL
Seelos Therapeutics Inc
15 Mar 24
Prospectus supplement
4:15pm
. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus … be no assurance the Nasdaq staff would grant any request for continued listing.
We intend to monitor the market value of our common stock and consider available
8-K
EX-10.1
xdc5rokxvnfdtn5
30 Jan 24
Entry into a Material Definitive Agreement
4:01pm
424B5
en5t6qs3 48ift
30 Jan 24
Prospectus supplement for primary offering
6:05am
8-K
EX-1.1
j9rew0edgqlcdfv
30 Nov 23
Seelos Therapeutics Announces Pricing of $5.55 Million Public Offering
4:59pm
424B5
tt456szd
30 Nov 23
Prospectus supplement for primary offering
4:58pm
424B5
fasnhw
28 Nov 23
Prospectus supplement for primary offering
4:06pm
8-K
jszqn3 er
3 Nov 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:15pm
424B3
yno05
29 Sep 23
Prospectus supplement
4:56pm
8-K
EX-10.1
yzfoi drti4nx
25 Sep 23
Entry into a Material Definitive Agreement
4:06pm
424B5
2jfkytdn3w
25 Sep 23
Prospectus supplement for primary offering
6:02am